Ranked on: #5 Top Health & Biotech Investors 2026 · #5 Top VC Firms in Boston 2026 (Ranked by Deals) · #8 Most Active Series A Investors of 2026 (Ranked) · Get your badge →
Is this your firm? Get featured or correct your listing →
At a glance
RA Capital appears in 6 funding rounds tracked by ValueAddVC since 2026, leading 3. Its most frequent sector in these rounds is Health & Biotech, and its most recent tracked deal was Estuary Biotherapeutics' $93M Series A round (Oct 16, 2026).
Strategy
Stages
SeedVentureGrowthCrossover
Sectors
HealthcareBiotechPlanetary Health
Geographies
USABoston, Massachusetts, USA
Check size
$5M-$100MRecent changes
- Oct 16, 2026Oct 16, 2026Invested in Estuary Biotherapeutics (Series A, $93M) FierceBiotech
- Sep 9, 2026Sep 9, 2026Invested in Solstice Oncology (Series A, $225M) GlobeNewswire
- Sep 6, 2026Sep 6, 2026Sectors updated: Healthcare, Biotech, Planetary Health racap.com
- Sep 6, 2026Sep 6, 2026Stages updated: Seed, Venture, Growth, Crossover racap.com
- Aug 27, 2026Aug 27, 2026Invested in AusperBio Therapeutics (Series C, $120M) BioSpace
Earlier changes (2)
- Aug 11, 2026Aug 11, 2026Invested in Infinimmune (Series A, $75M) Business Wire (via FinancialContent)
- Jul 2, 2026Jul 2, 2026Invested in Celea Therapeutics ($180M) Celea Therapeutics
Portfolio
7 totalRecent Investment Activity
6Track record: led 3 and participated in 3 of 6 tracked venture rounds · 6 in the last 12 months · led 2 Series A
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Estuary Biotherapeutics | Series A | Led | $93M | — | RA CapitalLeadunverifiedDeep Track CapitalunverifiedGoogle Ventures (GV)unverifiedBiogen New VenturesUPMC EnterprisesPivotal bioVenture PartnersNational Kidney Foundation Innovation Fund+1 more | FierceBiotech |
| Sep 9, 2026 | Solstice Oncology | Series A | Led | $225M | — | GlobeNewswire | |
| Aug 27, 2026 | AusperBio Therapeutics | Series C | Participated | $120M | — | Pulse story | |
| Aug 11, 2026 | Infinimmune | Series A | Participated | $75M | — | Regeneron VenturesLeadMedCity NewsPlayground GlobalLeadunverifiedMerck Global Health Innovation FundMedCity NewsCivilization VenturesMedCity NewsPear VCMedCity NewsRA CapitalunverifiedGoldcrest CapitalunverifiedGodfrey CapitalunverifiedEverbright BiofundForge Life Science PartnersWild Tree Ventures | Pulse story |
| Aug 6, 2026 | LifeMine Therapeutics | Series E | Participated | $188M | — | Business Wire via Yahoo Finance | |
| Jul 2, 2026 | Celea Therapeutics | funding round | Led | $180M | — | Celea Therapeutics |
Sector / Stage Activity
By stage (tracked rounds)
Series A
3 · 50%
Series C
1 · 17%
Series E
1 · 17%
Co-Investors
12ARCH Venture Partners · 2 sharedAndreessen Horowitz · 1 sharedBezos Expeditions · 1 sharedBlackstone Multi-Asset Investing · 1 sharedCanaan Partners · 1 sharedCivilization Ventures · 1 sharedCommodore Capital · 1 sharedDeep Track Capital · 1 sharedLeaps by Bayer · 1 sharedMonograph Capital · 1 sharedPureTech Health · 1 sharedTCGX · 1 shared
Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 16, 2026Biggest US Funding Rounds This Week: Modal's $750M LeadsCrunchbase's weekly ranking found just two U.S. rounds at or above $200M this week -- Modal Labs' $750M Series D and Icon's $200M Series D -- with investors otherwise sticking to the $60M-to-$135M range across AI, biotech and construction tech.→
- Oct 16, 2026Estuary Biotherapeutics Launches With $103M For Kidney Gene TherapyEstuary Biotherapeutics emerged from stealth with $103 million, including a $93 million Series A led by RA Capital, to advance gene therapies for a common inherited kidney disease.→
- Oct 15, 2026OrbiMed Raises $3B Across Two New Healthcare FundsOrbiMed closed $3 billion across two new vehicles, OrbiMed Private Investments X for US and European life sciences venture capital and OrbiMed Asia Partners VI for Asian healthcare growth equity, bringing the firm's total assets past $21 billion.→
- Sep 9, 2026Solstice Oncology Launches With $225M Series ASolstice Oncology launched with a $225 million Series A led by RA Capital Management to advance porustobart, a second-generation CTLA-4 immunotherapy licensed from Harbour BioMed, into two Phase 2 cancer trials.→
- Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity PillThe Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.→
- Aug 27, 2026AusperBio Raises $120M for Hepatitis B CureAusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.→
- Aug 11, 2026Infinimmune Raises $75M for Human-Derived Antibody DrugsInfinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance two atopic dermatitis antibody candidates built from its human-derived Anthrobody platform.→
- Jul 5, 2026Biotech VCs Are Betting Big on Single Clinical TrialsCelea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.→
- Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→
- Jul 2, 2026Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.→
- Jun 10, 2026SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→
RA Capital FAQ
What companies has RA Capital invested in?
RA Capital's portfolio includes Estuary Biotherapeutics, Solstice Oncology, AusperBio Therapeutics, Infinimmune, LifeMine Therapeutics, Celea Therapeutics, and 1 more tracked companies.
Who does RA Capital co-invest with most?
In the rounds Value Add tracks, RA Capital most often invests alongside ARCH Venture Partners (2 shared deals), Andreessen Horowitz (1 shared deal), Bezos Expeditions (1 shared deal), Blackstone Multi-Asset Investing (1 shared deal), Canaan Partners (1 shared deal).
Sources & methodologyshow
Where these figures come from
- Celea Therapeuticsprimary source1 fact
- GlobeNewswireprimary source1 fact
- FierceBiotechmajor outlet1 fact
- BioSpaceresearch database1 fact
- Business Wire (via FinancialContent)research database1 fact
- Business Wire via Yahoo Financeresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.